Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masaoki Ito

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
The Journal of Thoracic and Cardiovascular Surgery|February 19, 2022
The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinomaYasuhiro Tsutani, Masaoki Ito, Yoshihisa Shimada, et al.
Clinical Lung Cancer|November 6, 2013
Classifications of n2 non-small-cell lung cancer based on the number and rate of metastatic mediastinal lymph nodesMasaoki Ito, Yoshinori Yamashita, Yasuhiro Tsutani, et al.
Oncology Letters|March 15, 2019
Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesotheliomaYuichiro Kai, Yasuhiro Tsutani, Norifumi Tsubokawa, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|September 29, 2017
Postoperative complications and prognosis after lobar resection versus sublobar resection in elderly patients with clinical Stage I non-small-cell lung cancerYasuhiro Tsutani, Norifumi Tsubokawa, Masaoki Ito, et al.
Breast Cancer (Tokyo, Japan)|March 31, 2019
Correction to: Breast cancer cell motility is promoted by 14-3-3γEmiko Hiraoka, Takahiro Mimae, Masaoki Ito, et al.
Clinical Lung Cancer|July 29, 2021
Clinical Behavior of Combined Versus Pure High-Grade Neuroendocrine CarcinomaYoshinori Handa, Yasuhiro Tsutani, Masaoki Ito, et al.
Thoracic Cancer|October 13, 2021
Pathological high malignant grade is higher risk of recurrence in pN0M0 invasive lung adenocarcinoma, even with small invasive sizeMasaoki Ito, Yoshihiro Miyata, Kei Kushitani, et al.
Lung Cancer (Amsterdam, Netherlands)|February 9, 2020
Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysisMasaoki Ito, Yoshihiro Miyata, Yasuhiro Tsutani, et al.
JTO Clinical and Research Reports|January 1, 2024
Brief Report: circRUNX1 as Potential Biomarker for Cancer Recurrence in EGFR Mutation-Positive Surgically Resected NSCLCCarlos Pedraz-Valdunciel, Masaoki Ito, Stavros Giannoukakos, et al.
Annals of Translational Medicine|November 9, 2017
The combination of checkpoint immunotherapy and targeted therapy in cancerNiki Karachaliou, Maria Gonzalez-Cao, Aaron Sosa, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
The Journal of Thoracic and Cardiovascular Surgery|February 19, 2022
The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinomaYasuhiro Tsutani, Masaoki Ito, Yoshihisa Shimada, et al.
Clinical Lung Cancer|November 6, 2013
Classifications of n2 non-small-cell lung cancer based on the number and rate of metastatic mediastinal lymph nodesMasaoki Ito, Yoshinori Yamashita, Yasuhiro Tsutani, et al.
Oncology Letters|March 15, 2019
Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesotheliomaYuichiro Kai, Yasuhiro Tsutani, Norifumi Tsubokawa, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|September 29, 2017
Postoperative complications and prognosis after lobar resection versus sublobar resection in elderly patients with clinical Stage I non-small-cell lung cancerYasuhiro Tsutani, Norifumi Tsubokawa, Masaoki Ito, et al.
Breast Cancer (Tokyo, Japan)|March 31, 2019
Correction to: Breast cancer cell motility is promoted by 14-3-3γEmiko Hiraoka, Takahiro Mimae, Masaoki Ito, et al.
Clinical Lung Cancer|July 29, 2021
Clinical Behavior of Combined Versus Pure High-Grade Neuroendocrine CarcinomaYoshinori Handa, Yasuhiro Tsutani, Masaoki Ito, et al.
Thoracic Cancer|October 13, 2021
Pathological high malignant grade is higher risk of recurrence in pN0M0 invasive lung adenocarcinoma, even with small invasive sizeMasaoki Ito, Yoshihiro Miyata, Kei Kushitani, et al.
Lung Cancer (Amsterdam, Netherlands)|February 9, 2020
Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysisMasaoki Ito, Yoshihiro Miyata, Yasuhiro Tsutani, et al.
JTO Clinical and Research Reports|January 1, 2024
Brief Report: circRUNX1 as Potential Biomarker for Cancer Recurrence in EGFR Mutation-Positive Surgically Resected NSCLCCarlos Pedraz-Valdunciel, Masaoki Ito, Stavros Giannoukakos, et al.
Annals of Translational Medicine|November 9, 2017
The combination of checkpoint immunotherapy and targeted therapy in cancerNiki Karachaliou, Maria Gonzalez-Cao, Aaron Sosa, et al.
Pageof 7